Cannabis: research and patient questions (Page 3)

This review looked at many earlier studies to see whether using CBD products or hemp oil can cause a person to fail a drug test for cannabis. Most of the studies involved adult volunteers or patient reports, and they tested blood, urine, saliva and hair samples.

This review gathered brain scan studies in adults that gave cannabidiol, a non-intoxicating part of the cannabis plant, and compared it with a dummy pill while people were stressed or anxious. The authors combined the results from twelve small studies.

Researchers reviewed the best available medical studies that tested cannabis-based medicines in people with a long-lasting condition that causes widespread body pain, poor sleep and tiredness. They looked at a few different versions of these medicines and compared them with dummy pills or standard painkillers.

Researchers used large collections of genetic data from people with schizophrenia, a serious mental illness, and from people in several populations, and compared them with genetic data about the medicines people take. They then used computer methods to look for shared genetic patterns and possible drug targets. The study used existing records and computer analysis and did not treat or follow any patients.

This review looked at the latest research on counseling-based treatments for teenagers who use alcohol or drugs and are seen as outpatients, meaning they live at home and visit a clinic. It covered studies published from 2018 to 2023 and reviewed what works best, with a focus on marijuana and opioid use. The authors compared the findings against earlier reviews.

Older adults demonstrate diminished baseline levels of specific endocannabinoids and NAEs (AEA, DEA, LEA), reflecting age-related endocannabinoid system decline. However, acute cannabis administration effectively elevates circulating NAEs across all age groups, with older adults exhibiting even greater relative increases in AEA and DEA, highlighting potential therapeutic mechanisms for symptom management in aging populations.

While preclinical and early human studies suggest that oral and topical CBD may offer safe, adjunctive pain relief with minimal side effects, current clinical evidence remains inconclusive due to small sample sizes. Clinicians should counsel patients on the current paucity of robust data, potential significant costs, and the lack of product regulation when considering over-the-counter cannabinoid therapies.

This study involved patients diagnosed with Parkinson's disease who were given either a cannabidiol-enriched cannabis product or a placebo. The researchers aimed to see how effective the cannabis product was in improving symptoms of Parkinson's disease over an eight-week period. They measured various health outcomes to assess the impact of the treatment.

A social media-delivered motivational interviewing intervention via secret Facebook groups is a feasible, highly acceptable, and engaging approach to reach non-treatment-seeking emerging adults who use cannabis frequently. While preliminary behavioral effects were modest, the significant reduction in cannabis vaping days warrants evaluation in a fully powered, definitive clinical trial.

This protocol outlines the first randomized controlled trial evaluating a mobile health intervention (iCanChange) integrating CBT and motivational interviewing for cannabis use disorder in young adults with first-episode psychosis. If proven feasible and effective, this digital tool could bypass traditional barriers to specialized psychosocial care in early intervention psychiatric settings.